BRPI0919714A2 - domínio variável único de imunoglobulina, polipeptídeo isolado, ligante, ácido nucleico, vetor, célula hospedeira, e, método para produzir um polipeptídeo - Google Patents
domínio variável único de imunoglobulina, polipeptídeo isolado, ligante, ácido nucleico, vetor, célula hospedeira, e, método para produzir um polipeptídeoInfo
- Publication number
- BRPI0919714A2 BRPI0919714A2 BRPI0919714A BRPI0919714A BRPI0919714A2 BR PI0919714 A2 BRPI0919714 A2 BR PI0919714A2 BR PI0919714 A BRPI0919714 A BR PI0919714A BR PI0919714 A BRPI0919714 A BR PI0919714A BR PI0919714 A2 BRPI0919714 A2 BR PI0919714A2
- Authority
- BR
- Brazil
- Prior art keywords
- polypeptide
- ligand
- vector
- producing
- nucleic acid
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 2
- 108090000765 processed proteins & peptides Proteins 0.000 title 2
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10708508P | 2008-10-21 | 2008-10-21 | |
| PCT/EP2009/063655 WO2010046337A2 (en) | 2008-10-21 | 2009-10-19 | Ligands that have binding specificity for dc-sign |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0919714A2 true BRPI0919714A2 (pt) | 2015-12-08 |
Family
ID=42062429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0919714A BRPI0919714A2 (pt) | 2008-10-21 | 2009-10-19 | domínio variável único de imunoglobulina, polipeptídeo isolado, ligante, ácido nucleico, vetor, célula hospedeira, e, método para produzir um polipeptídeo |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20110257373A1 (enExample) |
| EP (1) | EP2356149A2 (enExample) |
| JP (1) | JP2012506237A (enExample) |
| KR (1) | KR20110071139A (enExample) |
| CN (1) | CN102257009A (enExample) |
| AR (1) | AR073905A1 (enExample) |
| AU (1) | AU2009306424A1 (enExample) |
| BR (1) | BRPI0919714A2 (enExample) |
| CA (1) | CA2740856A1 (enExample) |
| EA (1) | EA201100488A1 (enExample) |
| IL (1) | IL212086A0 (enExample) |
| MX (1) | MX2011004244A (enExample) |
| TW (1) | TW201019962A (enExample) |
| UY (1) | UY32189A (enExample) |
| WO (1) | WO2010046337A2 (enExample) |
| ZA (1) | ZA201102763B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201100485A1 (ru) * | 2008-10-21 | 2011-12-30 | Домантис Лимитед | Композиции для нацеливания на дендритные клетки |
| EP2793918B1 (en) * | 2011-12-19 | 2019-09-11 | The Rockefeller University | Hdc-sign binding peptides |
| WO2023028593A2 (en) * | 2021-08-27 | 2023-03-02 | University Of Georgia Research Foundation, Inc. | Targeted nanoparticles and their uses related to infectious disease |
| CN118184795B (zh) * | 2022-12-13 | 2025-03-21 | 成都维瑾柏鳌生物医药科技有限公司 | 抗hiv-1的重组蛋白及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU665440B2 (en) * | 1992-06-05 | 1996-01-04 | Dade Produktions Ag | Rabbit single domain antibody and use thereof |
| NZ540196A (en) * | 2002-11-08 | 2008-09-26 | Ablynx Nv | Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders |
| US9028816B2 (en) * | 2003-01-10 | 2015-05-12 | Ablynx N.V. | Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor |
| US20090005257A1 (en) * | 2003-05-14 | 2009-01-01 | Jespers Laurent S | Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire |
| DK1639011T3 (da) * | 2003-06-30 | 2009-02-16 | Domantis Ltd | Pegylerede enkelt-domæne antistoffer (dAb) |
| AU2004266034B2 (en) * | 2003-08-21 | 2011-01-27 | Lipotek Pty Ltd | In vivo targeting of dendritic cells |
| EA012622B1 (ru) * | 2004-06-01 | 2009-10-30 | Домэнтис Лимитед | Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки |
| US20090191217A1 (en) * | 2004-12-02 | 2009-07-30 | De Wildt Ruud M | Anti-IL-1R1 Single Domain Antibodies And Therapeutic Uses |
| KR20070094909A (ko) * | 2004-12-02 | 2007-09-27 | 도만티스 리미티드 | 혈청 알부민 및 ｇｌｐ-1 또는 ｐｙｙ를 표적으로 삼는이중특이성 도메인을 갖는 항체 |
| MX2007011356A (es) * | 2005-03-18 | 2008-03-10 | Domantis Ltd | Anticuerpos contra antigenos de candida. |
| JP2009518025A (ja) * | 2005-12-06 | 2009-05-07 | ドマンティス リミテッド | 細胞表面標的に対して結合特異性を有する二重特異性リガンドおよびその使用方法 |
| CA2632417A1 (en) * | 2005-12-06 | 2007-06-14 | Domantis Limited | Ligands that have binding specificity for egfr and/or vegf and methods of use therefor |
| AU2007209202A1 (en) * | 2006-01-24 | 2007-08-02 | Domantis Limited | Ligands that bind IL-4 and/or IL-13 |
| JP2010504970A (ja) * | 2006-09-26 | 2010-02-18 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アジュバントを増強するための組成物および方法 |
| WO2008070363A2 (en) * | 2006-10-31 | 2008-06-12 | Domantis Limited | Intrabodies |
| CN101182539A (zh) * | 2007-11-06 | 2008-05-21 | 浙江大学 | Dc-sign启动子荧光素酶报告质粒的构建方法 |
-
2009
- 2009-10-19 US US13/125,384 patent/US20110257373A1/en not_active Abandoned
- 2009-10-19 AR ARP090104011A patent/AR073905A1/es not_active Application Discontinuation
- 2009-10-19 AU AU2009306424A patent/AU2009306424A1/en not_active Abandoned
- 2009-10-19 EA EA201100488A patent/EA201100488A1/ru unknown
- 2009-10-19 JP JP2011531514A patent/JP2012506237A/ja active Pending
- 2009-10-19 MX MX2011004244A patent/MX2011004244A/es not_active Application Discontinuation
- 2009-10-19 EP EP09736603A patent/EP2356149A2/en not_active Withdrawn
- 2009-10-19 TW TW098135298A patent/TW201019962A/zh unknown
- 2009-10-19 BR BRPI0919714A patent/BRPI0919714A2/pt not_active IP Right Cessation
- 2009-10-19 WO PCT/EP2009/063655 patent/WO2010046337A2/en not_active Ceased
- 2009-10-19 KR KR1020117011399A patent/KR20110071139A/ko not_active Withdrawn
- 2009-10-19 CN CN2009801529594A patent/CN102257009A/zh active Pending
- 2009-10-19 CA CA2740856A patent/CA2740856A1/en not_active Abandoned
- 2009-10-20 UY UY0001032189A patent/UY32189A/es unknown
-
2011
- 2011-04-03 IL IL212086A patent/IL212086A0/en unknown
- 2011-04-13 ZA ZA2011/02763A patent/ZA201102763B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201102763B (en) | 2012-09-26 |
| MX2011004244A (es) | 2011-05-25 |
| WO2010046337A3 (en) | 2010-07-01 |
| JP2012506237A (ja) | 2012-03-15 |
| UY32189A (es) | 2010-05-31 |
| CA2740856A1 (en) | 2010-04-29 |
| CN102257009A (zh) | 2011-11-23 |
| US20110257373A1 (en) | 2011-10-20 |
| KR20110071139A (ko) | 2011-06-28 |
| AU2009306424A1 (en) | 2010-04-29 |
| EA201100488A1 (ru) | 2011-12-30 |
| TW201019962A (en) | 2010-06-01 |
| EP2356149A2 (en) | 2011-08-17 |
| WO2010046337A2 (en) | 2010-04-29 |
| IL212086A0 (en) | 2011-06-30 |
| AR073905A1 (es) | 2010-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0814781A2 (pt) | Proteína, sequência de ácido nucleico, método para a produção de ácido itacônico, vetor, célula hospedeira, e, uso de um ácido cis-aconítico | |
| BRPI0813242A2 (pt) | Proteína de ligação a antígeno isolada, ácido nucléico isolado, vetor, célula hospedeira isolada, método para a produção de uma proteína de ligação a antígeno, e, composição. | |
| BRPI0808104A2 (pt) | Métodos para preparar e para produzir um polipeptídeo, polipeptídeo, sequência de ácido nucleico isolada, construção de ácido nucleico, vetor de expressão recombinante, e, célula hospedeira recombinante | |
| BR112012024287A2 (pt) | anticorpo, composição farmacêutica, método, ácido nucleico, vetor de expressão e célula hospedeira | |
| BRPI0905076A2 (pt) | Polipeptídeo, anticorpo, região variável, cadeia pesada ou cadeia leve, gene, vetor, célula hospedeira, método para produzir o referido polipeptídeo, e composição farmacêutica compreendendo o mesmo | |
| BRPI0916964A2 (pt) | polipetídeo, anticorpo, ácido nucléico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição e uso do polipeptídeo | |
| BR112013024983A2 (pt) | portador eletricamente aquecível e radiador de painel, e método para sua produção. | |
| BRPI1011244A2 (pt) | método para tratar um distúrbio de hemorragia em um indivíduo, proteína de coagulação quimérica, molécula de ácido nucleico, vetor, e, célula | |
| BR112012010200A2 (pt) | sisitema de controle de acesso a veículo, metodo para controle de acesso a veículo | |
| BR112014001258A2 (pt) | método de tipagem de dna, e, conjuntos de iniciadores para tipagem de dna | |
| BR112013031810A2 (pt) | valenceno sintase, ácido nucleico, vetor de expressão, anticorpo, célula hospedeira e métodos para preparar valenceno e nootkatona | |
| BRPI1008441A2 (pt) | anticorpo humanizado, composição farmacêutica, método para tratar e prevenir um distúrbio de célula b em sujeito, composição de anticorpo anti-cd-20 humanizado, ácido nucléico isolado e célula hospedeira. | |
| BRPI0822099A2 (pt) | membro de ligação isolado, uso de um membro de ligação isolado, método parav tratar um distúrbio, molécula de ácido nucléico isolada, célula hospedeira, e, método para produzir um membro de ligação | |
| EP2203553A4 (en) | METHOD FOR PRODUCING PERFORATIBLE MICROWASH SYSTEMS | |
| BRPI0819165A2 (pt) | Anticorpos anti-vegf | |
| BRPI0814467A2 (pt) | Método, e, biocombustível | |
| WO2014194131A3 (en) | Systems and methods for sequencing in emulsion based microfluidics | |
| DK2404667T3 (da) | Hydrocracking-katalysator, fremgangsmåde til fremstilling af samme og anvendelse deraf | |
| BR112014003107A2 (pt) | sistema e método para redes de negócios relevantes baseadas em grupos controlados relevantes, em responsabilidades e em desempenho medido | |
| BR112012022046A2 (pt) | ''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''. | |
| PL3181581T3 (pl) | Przeciwciała o zmodyfikowanym powinowactwie do FcRn, które wspomagają klierens antygenu | |
| BRPI0923225A2 (pt) | metodo para sintese de acidos nucleicos modificados no atomo de fosforo | |
| BRPI0811699A2 (pt) | Método para acesso inter-rádio em tecnologia de células. | |
| BR112013030846A2 (pt) | vetor de expressão, célula hospedeira não humana, método para a fabricação de uma proteína e uso de um vetor de expressão | |
| BRPI0910286A2 (pt) | métodos para transformação de levedura |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |